 Home > Medical News > Latest Medical News > BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use

BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use

 Last Update: 2021-04-18
 Source: Internet
 Author: User

Tags

solid

immune antibodies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 9, 2021, the CDE official website showed that BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use, and the indication is advanced solid tumors.

BGB-A1217 is a TIGIT monoclonal antibody developed by BeiGene.

According to the registration of clinical trials, the phase I clinical trial of BGB-A1217 is expected to be launched in Australia on August 12, 2019, to evaluate the initial safety and tolerability of tislelizumab combined with BGB-A1217 in patients with advanced solid tumors Properties, pharmacokinetics and preliminary anti-tumor activity.

It is worth noting that overseas companies such as Genentech and Merck are also conducting research on TIGIT monoclonal antibodies, but most of them are in the phase I and II clinical trials.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.